Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J
2008; 29: 270–276.
Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA
2002; 287: 1308–1320.
Maron BJ, Towbin JA, Thiene G, et al. American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies. Circulation
2006; 113: 1807–1816.
Melacini P, Basso C, Angelini A, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J
2010; 31: 2011–2123.
Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med
2000; 342: 1778–1785.
Ostman-Smith I, Wettrell G, Riesenfeld TA. Cohort study of childhood hypertrophic cardiomyopathy: improved survival following highdose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol
1999; 34: 113–122.
Nugent AW, Daubeney PE, Chondros P, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation
2005; 112: 1332–1338.
Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation
2007; 115: 773–781.
Maron BJ, McKenna WJ, Danielson GK, et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). Eur Heart J
2003; 24: 1965–1991.
Nasermoaddeli A, Miura K, Matsumori A, et al. Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study. Heart
2007; 93: 711–715.
Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol
2003; 42: 873–879.
Ostman-Smith I, Wettrell G, Keeton B, Riesenfeld T, Holmgren D, Ergander U. Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. Cardiol Young
2005; 15: 632–642.
Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation
2006; 114: 216–225.
Grenier MA, Osganian SK, Cox GF, et al. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J
2000; 139: S86–S95.
Sluysmans T, Colan SD. Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol
2005; 99: 445–457.
Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy infants: clinical features and natural history. Circulation
1982; 65: 7–17.
Skinner JR, Manzoor A, Hayes AM, Joffe HS, Martin RP. A regional study of presentation and outcome of hypertrophic cardiomyopathy in infants. Heart
1997; 77: 229–233.
Decker JA, Rossano JW, Smith EO, et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol
2009; 54: 250–254.
Maron BJ. Hypertrophic cardiomyopathy in childhood. Pediatr Clin N Am
2004; 51: 1305–1346.
Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol
1993; 72: 970–972.
Lewin MB, Towbin JA, Thapar MK, Dreyer WJ, Feltes TF. The rare association of tetralogy of Fallot with hypertrophic cardiomyopathy. Report of 2 neonatal patients. Tex Heart Inst J
1997; 24: 215–217.
Carvalho AM, Diógenes TC, Jucá ER, Carvalho AF, Carvalho CF, Paes Júnior JN. Tetralogy of Fallot and hypertrophic cardiomyopathy: a rare association. Arq Bras Cardiol
2003; 80: 217–219; 214–216.
Will PM, Serrian JL, Dawson JT. An unusual case of cyanotic heart disease in a patient with patent foramen ovale and right ventricular hypertrophy. Clin Cardiol
1996; 19: 429–432.
Nishimura RA, Holmes DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med
2004; 350: 1320–1327.
McKenna WJ. The natural history of hypertrophic cardiomyopathy. Cardiovasc Clin
1988; 19: 135–148.
Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol
1998; 32: 1943–1950.
Moran AM, Colan SD. Verapamil therapy in infants with hypertrophic cardiomyopathy. Cardiol Young
1998; 8: 310–319.
McMahon CJ, Nagueh SF, Pignatelli RH, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation
2004; 109: 1756–1762.
Olivotto I, Gistri R, Petrone P, et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol
2003; 41: 315–321.
Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol
2005; 45: 697.
Cha Y-M, Gersh BJ, Maron BJ, et al. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol.
2007; 18: 1–5.